E D Crawford

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values
    E D Crawford
    Division of Urology, University of Colorado Health Sciences Center, Denver 80262, USA
    Prostate 38:296-302. 1999
  2. ncbi Southwest Oncology Group studies in bladder cancer
    E David Crawford
    Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 97:2099-108. 2003
  3. ncbi Epidemiology of prostate cancer
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:3-12. 2003
  4. ncbi Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:13-9. 2003
  5. ncbi Prostate cancer. Introduction
    E David Crawford
    Division of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:1-2. 2003
  6. ncbi Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado, USA
    J Urol 175:1422-6; discussion 1426-7. 2006
  7. ncbi PSA testing: what is the use?
    E David Crawford
    University of Colorado, Denver, CO 80262, USA
    Lancet 365:1447-9. 2005
  8. ncbi Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA
    BJU Int 95:1-5. 2005
  9. ncbi Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
    J Urol 175:1286-90; discussion 1290. 2006
  10. ncbi Understanding the epidemiology, natural history, and key pathways involved in prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Science Center, Denver, Colorado, USA
    Urology 73:S4-10. 2009

Research Grants

  1. TUMT verses Medical Therapy in Treatment of BPH
    E Crawford; Fiscal Year: 2005
  2. Phytotherapy of Prostateic Symptoms (POPW)
    E Crawford; Fiscal Year: 2007

Detail Information

Publications101 found, 100 shown here

  1. ncbi Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values
    E D Crawford
    Division of Urology, University of Colorado Health Sciences Center, Denver 80262, USA
    Prostate 38:296-302. 1999
    ..0 ng/ml or an age-specific reference range (ASRR) as an abnormal cutoff PSA value...
  2. ncbi Southwest Oncology Group studies in bladder cancer
    E David Crawford
    Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 97:2099-108. 2003
    ..SWOG accomplishments in bladder cancer are highlighted, and future strategies are discussed...
  3. ncbi Epidemiology of prostate cancer
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:3-12. 2003
    ..In contrast, mortality rates for men diagnosed with localized or regional disease increased gradually during most of the 1990s before decreasing slightly among white men and reaching plateaus among African Americans...
  4. ncbi Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:13-9. 2003
    ....
  5. ncbi Prostate cancer. Introduction
    E David Crawford
    Division of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:1-2. 2003
  6. ncbi Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado, USA
    J Urol 175:1422-6; discussion 1426-7. 2006
    ..We analyzed data from the placebo arm of the MTOPS trial to determine clinical predictors of BPH progression...
  7. ncbi PSA testing: what is the use?
    E David Crawford
    University of Colorado, Denver, CO 80262, USA
    Lancet 365:1447-9. 2005
  8. ncbi Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA
    BJU Int 95:1-5. 2005
  9. ncbi Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
    J Urol 175:1286-90; discussion 1290. 2006
    ..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States...
  10. ncbi Understanding the epidemiology, natural history, and key pathways involved in prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Science Center, Denver, Colorado, USA
    Urology 73:S4-10. 2009
    ..A substantial research effort has recently focused on understanding the pathways involved in the disease's emergence and progression, particularly the 5alpha-reductase pathway...
  11. ncbi A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    J Urol 175:533-6. 2006
    ..The safety, efficacy and pharmacokinetics of LA-2585, a new 6-month subcutaneous depot of leuprolide acetate (Atrix Laboratories, Fort Collins, Colorado) were investigated in patients with prostate cancer...
  12. ncbi Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..The efficacy appears to be greater in patients who can achieve a PSA nadir of 0.1 ng/mL or less after the start of treatment...
  13. ncbi Herbal and vitamin supplement use in a prostate cancer screening population
    Albaha Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 63:288-92. 2004
    ..Additional investigation is warranted into the reason some men are not receiving standard prescription medications for LUTS and whether reliance on alternative treatments is playing a role in this phenomenon...
  14. ncbi Artificial neural network model to predict biochemical failure after radical prostatectomy
    C Porter
    Department of Urology, Veterans Affairs Medical Center, Washington, DC, USA
    Mol Urol 5:159-62. 2001
    ..81. CONCLUSION: These results suggest that ANN models can predict PSA failure using readily available preoperative variables. Such predictive models may offer assistance to patients and physicians deciding on definitive therapy for CaP...
  15. ncbi Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
    R Bruce Montgomery
    University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA
    J Urol 178:1946-51; discussion 1951. 2007
    ..We evaluated the effect of body mass index on prostate specific antigen response, and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer...
  16. ncbi High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade
    Zinelabidine Abouelfadel
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Prostate Cancer 1:115-7. 2002
    ..Continued screening for prostate cancer is resulting in the diagnosis of more unfavorable cancers...
  17. ncbi Recent advances in hormonal therapy for advanced prostate cancer
    Siam Oottamasathien
    Department of Surgery, Division of Urology, University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:1047-52; discussion 1054-8. 2003
    ..Although hormonal therapy is an important treatment modality for advanced prostate cancer, long-term treatment carries significant side effects that need to be considered...
  18. ncbi Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW)
    A Barqawi
    Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 800010 0510, USA
    Int J Impot Res 17:370-4. 2005
    ..Moreover, race appears to constitute another neglected potential risk factor, which should be investigated further in future studies...
  19. ncbi Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network
    A M Ziada
    University of Colorado Health Sciences Center, Denver, Colorado 80602, USA
    Cancer 91:1653-60. 2001
    ..Continued investigation of this approach with larger data sets seems warranted...
  20. ncbi Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up
    Lionel L Banez
    Division of Urologic Surgery and the Duke Prostate Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    BJU Int 104:310-4. 2009
    ....
  21. ncbi Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range...
  22. ncbi Early versus late hormonal therapy: debating the issues
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center, Denver, Colorado 80010, USA
    Urology 61:8-13. 2003
    ..Thus, accumulating evidence provides a rationale for continued investigation into the use of early hormonal therapy in selected patients...
  23. ncbi Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    A Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Int J Impot Res 18:323-8. 2006
    ..Current recommendations are to exclude prostate cancer before initiating TRT in men over age 40 and to closely monitor men in the first year of testosterone replacement, followed by observation in subsequent years...
  24. ncbi Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer
    E David Crawford
    University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 21:27-32; discussion 33-4, 39. 2007
    ..In this review, we present the current status of our knowledge about this procedure and the most important challenges that need to be addressed. We also present the initial results with this approach at our center...
  25. ncbi Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer
    J T Batuello
    Artificial Neural Networks in CaP Project and the, Denver, Colorado 80209, USA
    Urology 57:481-5. 2001
    ..The risk curve provides a clinically useful tool that can be used to give patients a realistic assessment of their risk of LN spread...
  26. ncbi Terazosin, doxazosin, and prazosin: current clinical experience
    B Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, Colorado Health Science Center, Denver, Colorado 80262, USA
    Urology 58:49-54. 2001
    ..Pharmacokinetic activity, mode of action, clinical efficacy, and side effects of the selective alpha(1)-receptor blockers terazosin, doxazosin, and prazosin are reviewed...
  27. ncbi The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer
    A Barqawi
    University of Colorado Cancer Center, and Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80261, USA
    BJU Int 92:695-8. 2003
    ....
  28. ncbi Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program
    Al Baha Barqawi
    Section of Urologic Oncology, University of Colorado Health Science Center School of Medicine, Denver, Colorado, USA
    Urology 65:708-12. 2005
    ..To assess the effect of aging and body mass index (BMI) on both serum total prostate-specific antigen (tPSA) and complexed PSA (cPSA) from the results of the 2003 Prostate Cancer Awareness Week national screening database...
  29. ncbi A 72-year-old man with prostate cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 16:1014-6, 1119-21. 2002
  30. ncbi The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions
    Natalie J Serkova
    Department of Anesthesiology and Radiology, Biomedical MRI MRS, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Prostate 68:620-8. 2008
    ..In this study, proton nuclear magnetic resonance spectroscopy ((1)H-NMRS) is used to assess potential metabolic markers of prostate cancer (PCa) in human expressed prostatic secretions (EPS)...
  31. ncbi Preventing and treating the complications of hormone therapy
    Ravi J Kumar
    Urologic Oncology, University of Colorado Health Sciences Center, 4200 East 9th Avenue C 319, Denver, CO 80262, USA
    Curr Urol Rep 6:217-23. 2005
    ....
  32. ncbi The current use and future trends of focal surgical therapy in the management of localized prostate cancer
    Al B Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, CO, USA
    Cancer J 13:313-7. 2007
    ..In addition, we will discuss future promising tools in MIT such as photodynamic therapy and the target focal therapy approach as a new trend for the treatment of organ-confined low-volume disease...
  33. ncbi A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO 80045 0511, USA
    Cancer 107:266-74. 2006
    ..Preclinical data from prostate cancer cell lines suggested a synergistic effect of these therapies...
  34. ncbi The association of time of day and serum testosterone concentration in a large screening population
    E David Crawford
    Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
    BJU Int 100:509-13. 2007
    ....
  35. ncbi Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  36. ncbi Genitourinary malignancies
    Shandra S Wilson
    Department of Urologic Oncology, Anschuz Cancer, Aurora, CO 80010, USA
    Cancer Chemother Biol Response Modif 22:485-513. 2005
  37. ncbi Screening for prostate cancer in 2006: PSA in the 21st century
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, USA
    N C Med J 67:136-9. 2006
  38. ncbi Screening for prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA
    Clin Prostate Cancer 3:21-5. 2004
    ..These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer...
  39. ncbi The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms
    Al Baha Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, Colorado, USA
    BJU Int 100:853-7. 2007
    ..To assess the effect of tamsulosin on the Sexual Health Inventory for Men (SHIM) score in men diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)...
  40. ncbi Controversies of androgen ablation therapy for metastatic prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, 1665 North Ursula, Aurora, CO 80010, USA
    Curr Pharm Des 12:799-805. 2006
    ....
  41. ncbi Focal therapy in prostate cancer: future trends
    Al Barqawi
    University of Colorado Health Sciences Center, 4200 E. 9th Ave, C-319, Denver, Colorado 80262, USA
    BJU Int 95:273-4. 2005
  42. ncbi Intermediate- to high-risk prostate cancer patient treated with radiation therapy
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 18:1105-10. 2004
  43. ncbi Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Science Center, Mail Stop 8117, P O Box 6511, Aurora, CO 80045 0511, USA
    J Clin Oncol 26:1532-6. 2008
    ..Southwest Oncology Group (SWOG) study 9921 is a randomized, phase III, intergroup study to define the role of adjuvant chemotherapy in patients with high-risk prostate cancer...
  44. ncbi Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
    L Michael Glode
    Oncology Urology Department, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 98:1643-8. 2003
    ....
  45. ncbi Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer
    Christopher R Porter
    Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, Washington, USA
    Oncology (Williston Park) 17:1395-9; discussion 1399, 1403-6. 2003
    ..With the introduction of more complex prebiopsy variables, ANNs are in a commanding position for use in predictive models. Easy and immediate physician access to these models will be imperative if their full potential is to be realized...
  46. ncbi The management of high risk prostate cancer
    Bulent Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 169:1993-8. 2003
    ....
  47. ncbi Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities
    Adeyinka O Laiyemo
    Department of Medicine, Howard University College of Medicine, Howard University Cancer Center, Washington, DC 20060, USA
    J Natl Cancer Inst 102:538-46. 2010
    ..It is unclear whether the disproportionately higher incidence and mortality from colorectal cancer among blacks compared with whites reflect differences in health-care utilization or colorectal cancer susceptibility...
  48. ncbi SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study
    Catherine E Klein
    University of Colorado, Denver, Colorado, USA
    Prostate 52:264-8. 2002
    ..Topotecan is a new topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer...
  49. ncbi Artificial neural networks for predictive modeling in prostate cancer
    Eduard J Gamito
    University of Colorado Health Sciences Center, C 314, 200 East 9th Avenue, Denver, CO 80262, USA
    Curr Oncol Rep 6:216-21. 2004
    ..This article provides an overview of the theoretical basis of ANNs, how they function, their strengths and limitations, and examples of how ANNs have been used to develop predictive models for the management of prostate cancer...
  50. ncbi Screening for prostate cancer: current recommendations
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
    Urol Clin North Am 31:219-26. 2004
    ..It is hoped that prospective, randomized, long-term screening studies, such as the PLCO and ERSCP trials, will show improved survival using the admittedly imperfect PSA marker in prostate cancer screening...
  51. ncbi The benefits of early androgen blockade
    Paul D Maroni
    The University of Colorado at Denver and Health Sciences Center, Academic Office One Bldg, Aurora, CO 80045, USA
    Best Pract Res Clin Endocrinol Metab 22:317-29. 2008
    ..This review concentrates on high-level evidence to address common clinical situations in advanced and metastatic prostate cancer. Additionally, the side-effects of androgen blockade have become increasingly visible and relevant...
  52. ncbi The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali Ziada
    UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
    Prostate 60:332-7. 2004
    ..To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)...
  53. ncbi Radiation therapy after radical prostatectomy
    Ali M Ziada
    Division of Urology, University of Colorado, Denver, CO, USA
    ScientificWorldJournal 4:377-81. 2004
  54. ncbi Relationship of demographic and clinical factors to free and total prostate-specific antigen
    E P Gelmann
    Lombardi Cancer Center, Georgetown University, Washington, DC 20007-2197, USA
    Urology 58:561-6. 2001
    ..CONCLUSIONS: Demographic (age and race/ethnicity) and clinical (history of benign prostatic disease) variables had a moderate effect on the measures of PSA and fPSA and very little effect on %fPSA...
  55. ncbi Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy
    E David Crawford
    Radiation Oncology, Department of Pathology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
    BJU Int 96:999-1004. 2005
    ....
  56. ncbi Surgical management of prostate cancer: optimizing patient selections and clinical outcome
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, Denver, 80252, USA
    Surg Oncol Clin N Am 14:301-19. 2005
  57. ncbi Prostate cancer in a man with multiple previous cancers
    Thomas Flaig
    University of Colorado, Health Sciences Center, Aurora, Colorado, USA
    Oncology (Williston Park) 21:611-4. 2007
  58. ncbi Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733
    Celestia S Higano
    Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Cancer 112:2181-7. 2008
    ..Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients...
  59. ncbi A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
    Prostate 70:848-55. 2010
    ..The purpose of the current trial was to determine the tissue and blood effects of high-dose silybin-phytosome in prostate cancer patients...
  60. ncbi A 42-year-old woman with breast cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:614; discussion 615-20. 2003
    ..At this point, we recommend tamoxifen, with consideration to adding goserelin (Zoladex) if the patient does not remain amenorrheic. The patient chose to enter the Intergroup trastuzumab trial...
  61. ncbi Testosterone and the prostate: implications for the treatment of hypogonadal men
    Joshua D Holyoak
    Division of Urology, University of Missouri Health Sciences Center, Columbia, MO 65212, USA
    Curr Urol Rep 9:500-5. 2008
    ..Patients undergoing TRT should be monitored carefully for any evidence of prostatic disease...
  62. ncbi Impact of previous local treatment for prostate cancer on subsequent metastatic disease
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Urol 168:1008-12. 2002
    ..It may provide new opportunities for clinical trials...
  63. ncbi Dutasteride: novel milestones in prostate cancer chemoprevention
    K O Rove
    University of Colorado, Denver, Colorado, USA
    Drugs Today (Barc) 47:135-44. 2011
    ....
  64. ncbi A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer
    E D Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO, USA
    Prostate Cancer Prostatic Dis 13:162-7. 2010
    ..With or without treatment, prostate cancer is a significant clinical and economic burden to society. New strategies for treatment or cancer prevention could play a role in reducing this burden...
  65. ncbi Testosterone replacement therapy and the risk of prostate cancer: a perspective view
    A B Barqawi
    Section Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Int J Impot Res 17:462-3. 2005
    ..This perspective continues the debate, and offers a unique perspective from the vantage point of a uro-oncologist...
  66. ncbi Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review
    R Shabsigh
    Division of Urology, Maimonides Medical Center, Brooklyn, NY 11219, USA
    Int J Impot Res 21:9-23. 2009
    ..Testosterone therapy did not have a consistent effect on prostate-specific antigen levels...
  67. ncbi Controversies regarding screening for prostate cancer
    E David Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
    BJU Int 100:5-7. 2007
  68. ncbi PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Eur Urol 54:262-73. 2008
    ..Despite the substantive societal impact of prostate cancer, the medical community is currently divided on the balance between benefit and harm of screening for prostate cancer using prostate-specific antigen (PSA)...
  69. ncbi Should routine screening for prostate-specific antigen be recommended?
    Siam Oottamasathien
    Division of Urology, Box c319, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Arch Intern Med 163:661-2; discussion 666. 2003
  70. ncbi Minimally invasive surgery in prostate cancer: current and future perspectives
    Bulent Akduman
    University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, Aurora, Colorado 80010, USA
    Cancer J 11:355-61. 2005
    ..In this review we critically discuss the current knowledge and future perspectives of minimally invasive treatment in prostate cancer...
  71. ncbi Prostate cancer chemoprevention: an overview of United States trials
    Albaha Barqawi
    Division of Urologic Oncolgy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 171:S5-8; discussion S9. 2004
    ..CONCLUSIONS: Chemoprevention of prostate cancer is currently being tested in a wide range of clinical trials. These studies have the potential to fundamentally alter the current approach to prostate cancer management...
  72. ncbi Prostate cancer update
    S S Wilson
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Minerva Urol Nefrol 55:199-204. 2003
    ..Its diagnosis, evaluation, and treatment therapies are constantly evolving. This paper summarizes and clarifies the most up-to-date information on prostate cancer prevention and treatment...
  73. ncbi Use of artificial neural networks in prostate cancer
    A Errejon
    ANNs in CaP Project, Denver, Colorado 80209, USA
    Mol Urol 5:153-8. 2001
    ..We review the basic concepts behind ANNs and examine the role of this technology in selected applications in prostate cancer research...
  74. ncbi Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models
    Priya N Werahera
    Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Hum Pathol 35:798-807. 2004
    ..Moreover, our 3-dimensional computer modeling system improves upon other systems: It is more than a simple extension of the planimetric technique, and it is able to demarcate clearly the boundaries of Gleason grades just 1 grade apart...
  75. ncbi The role of LHRH antagonists in the treatment of prostate cancer
    E David Crawford
    Department of Urology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    Oncology (Williston Park) 23:626-30. 2009
    ..Presently, degarelix is the only LHRH antagonist approved for the treatment of advanced prostate cancer...
  76. ncbi The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Am J Clin Oncol 29:517-23. 2006
    ....
  77. ncbi Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Urology 75:502-9. 2010
    ..Particular emphasis is placed on the design of the second large-scale trial of a 5alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial...
  78. ncbi Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma
    Thomas D Denberg
    University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    BJU Int 98:335-40. 2006
    ..5 times more common than RP. Clinical trials are needed to rigorously assess the effects of different local treatment strategies on clinical outcomes in men with cT3 prostate carcinoma...
  79. ncbi A prospective study of lycopene and tomato product intake and risk of prostate cancer
    Victoria A Kirsh
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 15:92-8. 2006
    ..Evidence for protective associations in subjects with a family history of prostate cancer requires further corroboration...
  80. ncbi Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Daniel P Petrylak
    Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 98:516-21. 2006
    ..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
  81. ncbi Surgical factors influence bladder cancer outcomes: a cooperative group report
    Harry W Herr
    Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 22:2781-9. 2004
    ..2; P =.0001) and fewer than 10 nodes removed (v > or = 10; OR, 5.1; P =.002). CONCLUSION: Surgical factors influence bladder cancer outcomes after cystectomy, after adjustment for pathologic factors and neoadjuvant chemotherapy usage...
  82. ncbi Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109
    Isaac J Powell
    Wayne State University Medical Center, Detroit, Michigan, USA
    J Urol 168:2016-9. 2002
    ..A progression-free and overall 5-year survival of 70% and 90%, respectively, compares favorably to Radiation Therapy Oncology Group neoadjuvant trial outcomes for this stage of prostate cancer...
  83. ncbi Ten-year survival in patients with metastatic prostate cancer
    Catherine M Tangen
    The Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Clin Prostate Cancer 2:41-5. 2003
    ..Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged...
  84. ncbi Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study
    Christopher R Porter
    Department of Urology, State University of New York, Stony Brook, New York, USA
    Urology 60:831-5. 2002
    ..76) were constructed from a contemporary, prospective database. Such models may be useful to patients and physicians alike when assessing the diagnostic strategies available to detect prostate cancer...
  85. ncbi Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning
    Tracy R Glass
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Urol 169:164-9. 2003
    ..Risk stratification is helpful for designing clinical trials and individual treatment, and it should be incorporated into future reports of outcomes of patients with metastatic disease...
  86. ncbi Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)
    A Oliver Sartor
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 112:2393-400. 2008
    ..This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial...
  87. ncbi Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
    ....
  88. ncbi Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?
    Edith D Canby-Hagino
    Department of Urology, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Curr Urol Rep 6:183-9. 2005
    ..This evidence is examined and recommendations are made for identifying patients with metastatic prostate cancer who may benefit from definitive treatment of the prostate tumor...
  89. ncbi Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone
    Donna L Berry
    University of Washington, Seattle, WA 98195 7266, USA
    J Clin Oncol 24:2828-35. 2006
    ..While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP, the study also was designed to compare the palliation of disease-related symptoms...
  90. ncbi The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Cancer 107:489-96. 2006
    ..Although race alone was not a strong predictor of death or disease progression, the effect of the baseline HGB level on overall and progression-free survival varied significantly by race...
  91. ncbi Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia
    James R Marshall
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Epidemiol Biomarkers Prev 15:1479-84. 2006
    ..Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009...
  92. ncbi Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    Maha Hussain
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 24:3984-90. 2006
    ..2 ng/mL or less. CONCLUSION: A PSA of 4 ng/mL or less after 7 months of AD is a strong predictor of survival. This data should be used to tailor future trial design for D2 prostate cancer...
  93. ncbi Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
    ..However, the optimal management of these patients after radical prostatectomy is unknown...
  94. ncbi Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
    BJU Int 99:775-9. 2007
    ..To determine patterns of repeat prostate biopsy in a cohort of men undergoing prostate cancer screening who have a negative initial biopsy...
  95. ncbi Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study
    Anita L Sabichi
    University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:2178-84. 2006
    ..Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue...
  96. ncbi Prostate-specific antigen velocity and prostate cancer gleason grade and stage
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 109:1689-95. 2007
    ..The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enrolled in a prostate cancer screening trial...
  97. ncbi Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men
    Steven A Kaplan
    Diabetes Care 29:749; author reply 749-50. 2006
  98. ncbi Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
    Maha Hussain
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:8724-9. 2005
    ..The epothilones are a new class of tubulin-polymerizing agents with activity in taxane-sensitive and resistant tumor models. We evaluated ixabepilone (BMS-247550) in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  99. ncbi Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer
    Ashutosh Tewari
    Josephine Ford Cancer Center and Vattikuti Urology Institute, Henry Ford Health, System, Detroit, MI, USA
    BJU Int 96:29-33. 2005
    ..The PSA doubling time after recurrence may also be important, leading to the increased mortality of AA men with prostate cancer...
  100. ncbi Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting
    Christopher R Porter
    Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Urology 65:937-41. 2005
    ..To develop a model capable of predicting prostate biopsy outcomes in a large screening population, with independent validation in the referral setting...
  101. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA
    N Engl J Med 349:2387-98. 2003
    ..Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy...

Research Grants3

  1. TUMT verses Medical Therapy in Treatment of BPH
    E Crawford; Fiscal Year: 2005
    ..The PI has enlisted the support of consultants who will assist in this important evaluation. The results of this analysis will be critical in allocating health care resources. ..
  2. Phytotherapy of Prostateic Symptoms (POPW)
    E Crawford; Fiscal Year: 2007
    ..abstract_text> ..